Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week High – What’s Next?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $50.00 and last traded at $43.7750, with a volume of 636 shares. The stock had previously closed at $44.49.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Wells Fargo & Company boosted their price objective on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, December 11th. Bloom Burton raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 7th. JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $57.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus price target of $54.64.

Xenon Pharmaceuticals Stock Down 1.9%

The company has a market cap of $3.17 billion, a PE ratio of -10.54 and a beta of 0.97. The firm’s 50-day moving average is $42.63 and its 200-day moving average is $38.52.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.01. During the same quarter in the previous year, the business earned ($0.81) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 65,302 shares of company stock worth $2,924,128 in the last 90 days. Insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. increased its stake in shares of Xenon Pharmaceuticals by 11.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after acquiring an additional 142,452 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Xenon Pharmaceuticals in the third quarter worth about $325,000. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $32,000. Verition Fund Management LLC purchased a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $2,293,000. Finally, Quarry LP lifted its holdings in shares of Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.